Biodexa Pharmaceuticals plc Stock Price, News & Analysis

Biodexa Pharmaceuticals (Nasdaq: BDRX) announced on January 5, 2026 the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary and her election to the Board of Directors, effective immediately.

Ms Sharp joined Biodexa as Group Financial Controller in December 2019 and has assumed many CFO responsibilities during her tenure. Her prior roles include Assistant Director of Finance at Hywel Dda University Health Board (over 10,000 staff; budget ~£800 million) and senior finance roles at Chime Communications Group (revenues ~£570 million) from 1999 until early 2018. Stephen Stamp will relinquish his CFO and Company Secretary roles but will remain as Chief Executive Officer.

Biodexa Pharmaceuticals (Nasdaq: BDRX) priced a best efforts public offering expected to raise aggregate gross proceeds of approximately $10.0 million before fees and expenses. The offering consists of (i) 157,000 ADS Units (one ADS representing 100,000 ordinary shares plus two Series L warrants) at a combined price of $3.28 per ADS Unit, and (ii) 2,891,781 pre-funded units at $3.2799 each. Each Series L Warrant is immediately exercisable at $3.28 and expires five years after issuance. The company intends to use net proceeds for development programs, working capital and general corporate purposes. The offering is expected to close on December 19, 2025, subject to customary closing conditions; Maxim Group is sole placement agent and the SEC declared the registration statement effective on December 17, 2025.

Biodexa (Nasdaq: BDRX) announced enrolment of the first three European patients into the pivotal Phase 3 Serenta trial of eRapa for familial adenomatous polyposis (FAP) at the University of Bonn, Germany on December 1, 2025. The Serenta trial (NCT06950385) is a double‑blind, placebo‑controlled study of 168 patients randomized 2:1 to evaluate eRapa safety and efficacy.

All sites are identified and onboarding; nine additional European sites across the Netherlands, Spain, Denmark, and Italy are expected to activate in the next 2–3 months. The trial began US enrolment in August 2025 and is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.

Biodexa (Nasdaq: BDRX) activated the University of Bonn as the first European site for the registrational Phase 3 Serenta trial evaluating eRapa in familial adenomatous polyposis (FAP) on November 24, 2025.

The company said this follows approval of its Clinical Trial Application by the European Medicines Agency and cites collaborators Emtora Biosciences, CRO Precision for Medicine, and a $20 million grant from the Cancer Prevention and Research Institute of Texas. The randomized, double-blind, placebo-controlled Serenta trial (NCT06950385) began US enrollment in August 2025. Nine additional European sites across the Netherlands, Spain, Denmark, and Italy are expected to activate in the next 2–3 months. For eligibility and site details visit https://serentatrial.com/.

Biodexa (Nasdaq: BDRX) announced EMA approval of a Clinical Trial Application (CTA) for its pivotal Phase 3 Serenta trial in familial adenomatous polyposis (FAP) on November 3, 2025. The trial will open initially in Denmark, Germany, Netherlands, and Spain with Italy expected to be added later. The U.S. arm enrolled its first patient in mid‑August 2025. Serenta is a randomized, double‑blind, placebo‑controlled Phase 3 registrational study planned to recruit 168 patients randomized 2:1 drug:placebo. Management cites a $7 billion addressable US–European market and expects the first European patient in 4Q 2025.

Biodexa (Nasdaq: BDRX) will host a breakfast symposium titled “FAP mechanisms and Chemoprevention Trial Issues” at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA‑IGC) annual meeting in St. Louis, MO, during Oct 9–11, 2025, with the event scheduled for October 11, 2025.

Speakers include guest presenter Dr Patrick Lynch and a panel with Sonia S. Kupfer MD and Paul E. Wise MD. Biodexa highlighted the timing as pivotal for its FAP program while advancing the Phase 3 Serenta trial of eRapa, an oral rapamycin formulation, and noted participation by several Phase 3 clinical investigators.

Biodexa Pharmaceuticals (NASDAQ:BDRX) reported interim results for H1 2025, highlighting significant progress in its clinical pipeline. The company's lead candidate eRapa entered Phase 3 trials for FAP with first patient enrollment in Puerto Rico, while securing Orphan Drug Designation in Europe. The company also initiated a Phase 2a study of tolimidone in Type 1 Diabetes.

Financial highlights include a $35 million Equity Line of Credit with C/M Capital Master Fund LP, and a $3 million grant awarded to collaboration partner Emtora Biosciences. R&D costs decreased to £1.67 million (from £2.19M in 1H24), while cash balance stood at £4.04 million as of June 30, 2025.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has initiated its Phase 3 trial for eRapa, a proprietary encapsulated rapamycin treatment for familial adenomatous polyposis (FAP). The company received an additional $3 million grant from the Cancer Prevention & Research Institute of Texas, bringing total non-dilutive funding to $20 million for the Phase 3 trial.

The Phase 2 trial showed promising results with a 29% median decrease in polyp burden and 89% non-progression rate at 12 months in cohort 2. The Phase 3 study will involve 168 patients across approximately 30 clinical sites in the U.S. and Europe. With Fast Track status and Orphan Drug designation, Biodexa is positioned to be first-to-market in an estimated $7.3 billion addressable market with no current therapeutic options.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the enrollment of its first two patients in the pivotal Phase 3 Serenta trial for eRapa, targeting Familial Adenomatous Polyposis (FAP). The trial will be conducted across 30 sites (20 in US, 10 in Europe) and will evaluate 168 patients in a 2:1 drug/placebo randomized study.

The company aims to develop the first non-surgical treatment for FAP, a hereditary condition that typically leads to colorectal cancer if untreated. The program has received $20 million in grant funding from CPRIT and targets a $7.3 billion addressable market. The trial follows promising Phase 2 results and represents a potential breakthrough in FAP treatment, where currently only surgical resection is available.